SCHEMBL652132

SCHEMBL652132

Cc1ccc(/N=C2/NC(=O)/C(=C/c3cnc(NC(=O)C4CC4)s3)S2)c(C)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.55
NPSR1 Q6W5P4 5/20 0.55
RECQL P46063 1/20 0.55
LMNA P02545 4/20 0.54
TDP1 Q9NUW8 3/20 0.52
L3MBTL1 Q9Y468 3/20 0.52
MAPK1 P28482 2/20 0.52
POLB P06746 2/20 0.51
HPGD P15428 1/20 0.51
RNASEL Q05823 1/20 0.44
LCK P06239 1/20 0.43
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
ABL1 P00519 1/20 0.38
ALOX15 P16050 1/20 0.38
PTGS2 P35354 1/20 0.38
PLA2G1B P04054 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651038 0.94 MAPT (0.50) MAPTNPSR1RECQLLMNATDP1
SCHEMBL10227590 0.92 MAPT (0.46) MAPTNPSR1RECQLLMNATDP1
SCHEMBL652062 0.90 MAPT (0.56) MAPTNPSR1RECQLLMNATDP1
SCHEMBL652061 0.90 MAPT (0.56) MAPTNPSR1RECQLLMNATDP1
SCHEMBL10176547 0.90 MAPT (0.47) MAPTNPSR1RECQLLMNATDP1
SCHEMBL13091512 0.89 MAPT (0.56) MAPTNPSR1RECQLLMNATDP1
SCHEMBL10176469 0.88 MAPT (0.54) MAPTNPSR1RECQLLMNATDP1
SCHEMBL10176532 0.87 PTPN7 (0.44) MAPTNPSR1RECQLLMNATDP1
SCHEMBL12382988 0.87 MAPT (0.53) MAPTNPSR1RECQLLMNATDP1
SCHEMBL651049 0.87 MKNK1 (0.42) MAPTNPSR1RECQLLMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
WO-2010122979-A1 THIAZOLIDINONE DERIVATIVE SBIバイオテック株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MAPT 3657/4885NPSR1 4464/4885RECQL 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.